Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (191-200 of 283) with videos related to

Pageof 29
Sort By:
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
British Journal of Haematology|February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial resultsPaul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Somatic mutation phasing and haplotype extension using linked-reads in multiple myelomaSteven M Foltz, Yize Li, Lijun Yao, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Pageof 29

Showing results (191-200 of 283) with videos related to

Sort By:
Pageof 29
Cancer|February 7, 2025
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 StudyMarlise R Luskin, Jun Yin, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2020
First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple MyelomaRavi Vij, Rajneesh Nath, Daniel E H Afar, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Blood|October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myelomaShaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
Blood|March 16, 2017
Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graftMark A Schroeder, Michael P Rettig, Sandra Lopez, et al.
British Journal of Haematology|February 14, 2018
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial resultsPaul G Richardson, William I Bensinger, Carol Ann Huff, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Somatic mutation phasing and haplotype extension using linked-reads in multiple myelomaSteven M Foltz, Yize Li, Lijun Yao, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502Steven M Devine, Kouros Owzar, William Blum, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Pageof 29